Table 1 Summary of the published studies included in the meta-analysis and system analysis
PumID | Published year | Detection method | Cases (N) | Mean age | Tumor Stage | Pathological diagnosis | Cutoff | Biomarker | Patients with high level of CTCs (n) |
|---|---|---|---|---|---|---|---|---|---|
29,110,843 | 2017 | size-based microfilter assay | 40 | 67 | I/II/III | Adenocarcinoma | ≥1/7.5 mL | N.A. | 15 |
28,919,743 | 2017 | NanoVelcro | 143 | (−) | I/II/III/IV | Adenocarcinoma | ≥1/1 mL | CK+/CD45−/DAPI+, | 37 |
28,633,480 | 2017 | CellSearch | 125 | 61 | I/II/III | Squamous/ Adenocarcinoma/Others | ≥5/7.5 mL | CK+/CD45−/DAPI+, | 24 |
28,492,516 | 2017 | ScreenCell Cyto | 73 | 67 | IV | Squamous/ Adenocarcinoma | > 6/3 mL | N.A. | 34 |
28,474,575 | 2017 | CellSearch | 107 | 65 | III/IV | NSCLC | ≥5/7.5 mL | CK+/CD45−/DAPI+, | 17 |
28,289,866 | 2017 | CellSearch | 59 | 60 | III/IV | Squamous/ Adenocarcinoma/Others | ≥2/7.5 mL | CK+/CD45−/DAPI+, | 24 |
27,983,527 | 2017 | CellSearch | 100 | 62 | III/IV | Squamous Cancer | ≥5/7.5 mL | CK+/CD45−/DAPI+, | 9 |
26,661,896 | 2015 | Cyttel method | 46 | (−) | III/IV | Squamous/ Adenocarcinoma | ≥8/3.2 mL | CD45- | 7 |
21,422,424 | 2010 | CellSearch | 101 | 67 | III/IV | Squamous/Poorly differentiated/ Adenocarcinoma/Others | ≥5/7.5 mL | CK+/CD45−/DAPI+, | 9 |
21,098,695 | 2010 | ISET | 208 | 63 | I/II/III/IV | Squamous/ Adenocarcinoma/Large cell carcinoma/Sarcomatoid carcinoma | ≥50/10 mL | N.A. | 64 |